Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sandoz Expands Kundl Site Sterile Production

Published: Tuesday, March 12, 2013
Last Updated: Tuesday, March 12, 2013
Bookmark and Share
Production expansion will create 30 new jobs at the site and reinforces the Kundl site’s position as a leading producer of sterile injectables.

Sandoz has officially opened its new facilities in Kundl, Austria, thereby expanding the production of sterile penicillins at the site significantly and creating 30 new jobs.

With the expansion, Kundl has added two new floors to its existing building and increased its powder facilities from 10 to 12 with a planned annual capacity of more than 150 million vials.

Approximately 190 million packs of medicinal products are distributed annually from the Kundl site to around 100 countries.

Kundl is Sandoz’s largest production site and one of the world's leading antibiotics manufacturers as well as the last remaining fully integrated penicillin producer in the western world. Currently 200 employees work in the sterile penicillins production.

The size of the two new floors is approximately 22,500 m³ which equates to about 22 single-family homes. Together with the current space of 26,300 m³, the site will be equivalent in size to 48 single-family homes.

Jeff George, Global Head of Sandoz, said: “Expanding our sterile production in Kundl demonstrates our focus on differentiated products and our commitment to Austria. The significant expansion of our sterile production will also play a major role in strengthening innovation at the Kundl site.”

"We have decided to expand our production of sterile penicillins due to strong worldwide demand for antibiotics. The additional lines increase security of supply for the market and allow us to respond quickly to changing needs in the fast-paced generics business.” said Ernst Meijnders, Chairman of the Executive Board of Sandoz GmbH in Austria.

The guests at the opening included local politicians, representatives from industry, Kundl village’s priest, Dr. Piotr Stachiewicz, as well as Tyrol’s Governor Günther Platter.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sandoz Achieves Important Milestones on Phase III Trials for Key Biosimilars Programs
Company is currently preparing to file Filgrastim in the US and pegfilgrastim in the US and EU.
Tuesday, May 06, 2014
Sandoz Receives Japanese Approval for Biosimilar Filgrastim
Approval paves the way for this oncology medicine to be made available to oncology patients in Japan.
Monday, March 24, 2014
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!